COMP <GO>
DERM vs NGEN // EV/EBITDA & P/E VALUATION
Journey Medical Corporation (NASDAQ) VS. NervGen Pharma Corp. (NASDAQ) • 15-METRIC TALLY: DERM 1
— NGEN 1
■ METRIC PARITY
LAST: $5.17 (-4.44%) • MKT CAP: $152.7M
valuation
—
LAST: $1.37 (-4.86%) • MKT CAP: $155.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DERM VS. NGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DERM | NGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -19.50% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.15% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -13.30% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -18.70% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 11.10% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.74 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.5 | 34.7 | +5.75 | DERM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $152.7M | $155.0M | -$2.3M | NGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DERM REV | NGEN REV | DERM GROSS % | NGEN GROSS % | DERM FCF | NGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.2M | — | 65.8% | — | -$12.4M | — |
| FY 2024 | $55.1M | — | 62.1% | — | -$9.1M | — |
| FY 2023 | $59.7M | — | — | — | $5.2M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DERM // BETA —
NGEN // BETA —